Click Title for complete article or
click Summary for overview of each
article.
Diabetes
and Pre-Diabetes Accounted for $218 Billion in
Costs in 2007, Health Affairs Paper
Demonstrates
From PR Newswire US -
Jan 13,
2010
PRINCETON,
N.J., Jan. 13A new analysis found that the cost of
diabetes and pre-diabetes reached $218 billion in
2007, with the exploding number of cases of type 2
diabetes responsible for the majority of the
costs. According to the study, diagnosed type 2
diabetes accounted for $174.4 billion of 2007
spending on diabetes and undiagnosed type 2
diabetes was responsible for $18 billion in
costs.
[ Summary
]
REMS
Assessment Webinar to Examine How to Measure
Effectiveness of Drug Safety
Plans
From PR
Newswire US - Jan 12,
2010
WILMINGTON,
Del., Jan. 12More than 80 Risk Evaluation and
Mitigation Strategy plans have been approved by
the Food & Drug Administration since their
inception in March 2008.
[ Summary
]
| FDA: New Treatments and
Technology |
| Click Title for complete article or
click Summary for overview of each
article.
Novartis
launches schizophrenia drug Fanapt in
US
From M2
Europharma - Jan 13,
2010
13 January
2010 - Swiss Novartis said on Monday it has
launched in the US Fanapt tablets for the acute
treatment of schizophrenia in adults. Fanapt, a
twice-daily, oral antipsychotic, was approved by
the US Food and Drug Administration in May
2009.
[ Summary
]
Biovista
Inc. and FDA to Collaborate on a Medication Safety
Initiative
From PR Newswire Europe & UK
Disclose - Jan 12,
2010
Biovista Inc.
today announced that the U.S. Food and Drug
Administration has licensed its technology
platform to help analyze, identify, and better
understand the way certain drugs can cause harmful
side effects.
[ Summary
]
FDA,
Vical Licensee Agree on Phase III Design for
Collategene
From BioWorld Today -
Jan 12,
2010
Vical Inc.
said licensee AnGes MG Inc. reached an agreement
with the FDA on the design of a 560-patient Phase
III trial of Collategene, a potential treatment
for patients with peripheral arterial disease. But
AnGes is unlikely to start the Phase III
Collategene trial until it receives approval of
the drug in Japan, where the product currently is
under review, according to Vical.
[ Summary
]
Spherix
Completes Enrollment in NEET, a Phase 3 Clinical
Trial Evaluating an Oral Drug for Type 2
Diabetes
From PR Newswire US -
Jan 12,
2010
BETHESDA, Md.,
Jan. 12Spherix Inc., an innovator in biotechnology
for diabetes therapy, and a provider of technical
and regulatory consulting services to food,
supplement, biotechnology and pharmaceutical
companies, today announced the completion of
patient enrollment in its global Phase 3 clinical
trial NEET, which is evaluating the safety and
efficacy of D-tagatose as an oral treatment for
Ty...
[ Summary
]
FDA
Grants Orphan Drug Status to Allon's Davunetide
for Brain Disease
From Market Wire - Jan 12, 2010
01/12/10 -- Allon Therapeutics Inc.
announced today that the United States Food and
Drug Administration has granted Orphan Drug
Designation to the Company's lead neuroprotective
drug candidate davunetide for the treatment of
Progressive Supranuclear Palsy, a
rapidly-progressing and fatal degenerative brain
disease.
[ Summary
]
FDA
Unveils First Phase of Transparency
Initiative
From PharmaLive News Archive -
Jan 11,
2010
ROCKVILLE,
Md., Jan. 12, 2010--The U.S. Food and Drug
Administration today unveiled the first phase of
its Transparency Initiative which is designed to
explain agency operations, how it makes decisions,
and the drug approval process.
[ Summary
]
Pisgah
Labs, Inc. Tackles Prescription Drug Abuse As It
Files Eighth Patent
From PR Newswire US -
Jan 12,
2010
PISGAH FOREST,
N.C., Jan. 12According to the Office of National
Drug Control Policy, prescription drug abuse is
more prevalent than abuse of cocaine, heroin and
methamphetamine.
[
Summary
]
Click Title for complete article or
click Summary for overview of each
article.
Congressional
Documents and Publications
From Congressional Documents
& Publications - Jan 12, 2010
SCHUMER, KLOBUCHAR REVEAL NEW GOV'T
REPORT SHOWING 500% INCREASES IN PRESCRIPTION DRUG
PRICES--SAY MEDICARE SHOULD BE ALLOWED TO
NEGOTIATE WITH BIG PHARMA UNDER HEALTH REFORM
BILL. WASHINGTON, DC--Today, U.S. Senators Charles
E. Schumer and Amy Klobuchar revealed a new
government report showing that prices for more
than 400 brand-name drugs have spiked by as much
as 500 percent.
[
Summary
]
Click Title for complete article or
click Summary for overview of each
article.
Octapharma
receives Orphan Drug Exclusivity Approval for
wilate(R) - the First Replacement Therapy
Developed Specifically for von Willebrand
Disease
From
PR Newswire Europe & UK Disclose -
Jan 13,
2010
- Milestone
Marks Swiss Company's Entrance into the U.S. Blood
Coagulation Market. Octapharma AG, one of the
largest plasma products manufacturers in the
world, today announced that it has received orphan
exclusivity approval for wilate from the U.S. Food
and Drug Administration.
[ Summary
]
Structural
Study of PI3 Kinase Suggests Targeting
Strategies
From BioWorld Today -
Jan 12,
2010
When subtypes
of PI3 kinases - a type of kinase that is
frequently mutated in cancers, and hotly pursued
by drug developers in both biotech and pharma -
were discovered, their specific targeting at first
looked like something of a fool's
errand.
[ Summary
]
Study:
Era of Rapid Growth in Biomedical Research
Over
From PR
Newswire US - Jan 12,
2010
ROCHESTER,
N.Y., Jan. 12After a decade of remarkable growth,
total annual funding for biomedical research in
the U.S. has decelerated and may have even fallen
when adjusted for inflation. "The era of rapid
expansion in biomedical research funding that
began in the 1990's has ended," said Ray Dorsey,
M.D., a neurologist at the University of Rochester
Medical Center and lead author of the
study.
[ Summary
]
Zavesca
(miglustat) receives positive vote from the FDA's
Endocrinologic and Metabolic Drugs Advisory
Committee for the treatment of Niemann-Pick type C
disease
From
Hugin (English) - Jan
12, 2010
Actelion
Pharmaceuticals Ltd / Zavesca receives positive
vote from the FDA's Endocrinologic and Metabolic
Drugs Advisory Committee for the treatment of
Niemann-Pick type C disease processed and
transmitted by Hugin AS.
[ Summary
]
Epilepsy
Pipeline Update 2010 Showcasing New and Promising
Epilepsy Therapies to Be Held in San
Francisco
From PR Newswire US -
Jan 12,
2010
February 25-26
Forum to Bring Together Innovators, Clinicians and
Investors. MIDDLEBURG, Va., Jan. 12The Epilepsy
Therapy Project, a non-profit organization
dedicated to advancing new therapies for people
living with epilepsy, announces the Epilepsy
Pipeline Update 2010 conference, an in-depth,
2-day forum to be held February 25-26, 2010, at
the Hyatt Embarcadero Hotel in San
Francisco.
[ Summary
]
NOVAVAX
Announces Positive Preclinical Results for its
Respiratory Syncytial Virus (RSV) Vaccine
Candidate
From PR Newswire US -
Jan 12,
2010
ROCKVILLE,
Md., Jan. 12Novavax, Inc. announced today that it
has successfully completed a pre-clinical safety
and efficacy study of its RSV vaccine candidate in
cotton rats. In the current study, Novavax tested
its RSV-F vaccine candidate in cotton rats, a well
accepted animal model for RSV infection and
disease.
[ Summary
]
New
Clinical Study Shows Anxiolytic Potential of
CeNeRx's Novel Mechanism HPA Axis Modulator
Compounds
From PR Newswire US -
Jan 12,
2010
RESEARCH
TRIANGLE PARK, N.C., Jan. 12CeNeRx BioPharma,
Inc., a clinical stage company developing and
commercializing innovative treatments for diseases
of the central nervous system, today reported that
a new clinical study shows that its
investigational compound CXB722 has potential as a
novel anxiolytic, demonstrating a significant
effect on both endocrine and cardiovascular
biomarkers associ...
[ Summary
]
Click Title for complete article or
click Summary for overview of each
article.
MDRNA
Reports Potent Anti-Tumor Activity Against
Multiple Targets in Liver and Bladder
Cancer
From
Market Wire - Jan 13,
2010
01/13/10 --
MDRNA, Inc., a leading RNAi-based drug discovery
and development company, reported today in vivo
data for bladder and liver cancer demonstrating
further advancement of the Company's oncology
programs.
[ Summary
]
Kidney
Cancer Mutations Put Chromatin in the
Spotlight
From BioWorld International -
Jan 12,
2010
LONDON - A
mission to sequence certain genes from more than
100 kidney cancer samples has identified several
groups of mutations involved in packaging
chromatin, the three-dimensional mix of proteins
that support DNA. As well as casting light on the
genetic causes of that type of cancer, the
findings provide fresh targets for the development
of new cancer treatments.
[ Summary
]
Melanoma
Stem Cells' Evasive Talents
From PharmaLive News Archive -
Jan 11,
2010
BOSTON, Jan.
12 /PRNewswire-USNewswire/ -- Melanoma, if not
detected in its early stages, transforms into a
highly deadly, treatment-resistant cancer.
Although the immune system initially responds to
melanoma and mounts anti-tumor attacks, these
assaults are generally ineffective, allowing more
advanced melanomas to win the battle and spread
beyond the primary site. Now, researchers at
Children's Hospital Boston and Brigham and Women's
Hospital (BWH) shed light on how melanomas
stimulate, yet ultimately evade, a patient's
immune system. Their work, published online
January 12 by the journal Cancer Research, also
suggests ways drugs might block these
tactics.
[ Summary
]
Entest
BioMedical Inc. (OTCBB: ENTB) Obtains Specimen to
Be Used in Immunotherapeutic Cancer Vaccine
Research
From Market Wire - Jan 12, 2010
01/12/10 -- Entest BioMedical Inc.
announced it has obtained its first tumor
specimen, a canine parathyroid tumor to be
utilized in the development of Entest's
immunotherapeutic cancer vaccine. Company Chairman
David Koos said, "This is a major step in moving
forward in the development of our
immunotherapeutic cancer vaccine.
[ Summary
]
TD2
and Critical Outcome Technologies Inc. Develop
Novel Anti-Cancer Drug
From Marketwire (Canada) -
Jan 12,
2010
SCOTTSDALE,
ARIZONA and LONDON, ONTARIO-- - TGen Drug
Development and Critical Outcome Technologies Inc.
announced today that they will work together to
obtain approval of clinical trials for a promising
new anti-cancer drug called COTI-2. This easily
synthesized small molecule compound was discovered
and developed by COTI of London, Ontario,
Canada.
[ Summary
]
Spectrum
completes patient enrollment in Phase III trial of
apaziquone in bladder cancer
From M2 Europharma -
Jan 12,
2010
12 January
2010 - US Spectrum Pharmaceuticals said today it
has completed the enrollment of patients in the
second of two Phase III pivotal clinical trials of
apaziquone in non-muscle invasive bladder cancer.
The completion of the enrollment triggered USD1.5m
milestone payment to Spectrum under its
collaboration agreement with US peer
Allergan.
[ Summary
]
M.
D. Anderson News Release: Growth Factor Hit by
Cancer Drugs also Protects
Heart
From
PharmaLive News Archive - Jan 11, 2010
HOUSTON, Jan. 12, 2010 ? A growth
factor that is a common target of cancer drugs
also plays an important role in the heart's
response to stress, researchers at The University
of Texas M. D. Anderson Cancer Center report
online this week in the Journal of Clinical
Investigation.
[ Summary
]
Pathway
Studio, ChemEffect Module deployed at M. D.
Anderson to Investigate the Mechanism of Drug
Action and to Identify Approved Drugs that can
Synergize the Therapeutic Effect of
L-asparaginase, a Common Therapy for
Leukemia
From PharmaLive News Archive -
Jan 11,
2010
ROCKVILLE, MD,
January 12, 2010 ? Ariadne announces that The
University of Texas M. D. Anderson Cancer Center
has upgraded their Pathway Studio installation
with Ariadne?s ChemEffect drug-centric module.
This module, along with Pathway Studio?s
protein-centric data, is assisting M. D.
Anderson?s research pipeline aimed at enhancing
therapeutic utility of the enzyme-drug
L-Asparaginase (L-ASP).
[ Summary
]
Mandy
Moore Joins the Gynecologic Cancer Foundation to
Fight Cervical Cancer
From PR Newswire US -
Jan 12,
2010
CHICAGO, Jan.
12In recognition of Cervical Health Awareness
Month, singer-songwriter and actress Mandy Moore,
The Gynecologic Cancer Foundation and
GlaxoSmithKline are teaming up to encourage young
women to do their part to help reduce their risk
of cervical cancer.
[ Summary
]
NAMCP's Medical
Directors Resource Centers
The
purpose of NAMCP's Medical Directors Resource
Centers is to provide Medical Directors with
access to disease specific information and
resources and to improve patient
outcomes.
Accessing NAMCP's Medical
Directors Resource Centers will allow you
to:
Use screening tools to diagnose
Access treatment and best practice guidelines
Improve patient adherence and compliance
Improve patient outcomes
Better manage patients
Review cost of treatment versus overall
economic burden
Provide resources for your network physicians
Provide resources for patients
CLICK
HERE to access the Obesity Resource
Center
CLICK
HERE to access the Sleep Resource
Center
CLICK
HERE to access the Diabetes Resource
Center
Sign
Up Today for the Exclusive Medical Director's
Website
Click
here to sign up for free access to
the exclusive Medical Director's Website. Features
include a discussion forum, career information,
and consolidated clinical links to important
managed care websites. You must be a Medical
Director to gain access to the website. Keep
current on all of the issues surrounding Medical
Directors in today's market. Access is free
for all Medical Directors. Please contact Jeremy
Williams at jwilliams@namcp.org
for more information! For those of you who are
not Medical Directors, please forward the link or
eNews to any Medical Directors in your company
that may be interested in the website.
CLICK THE FOLLOWING TITLES
TO PARTICIPATE IN THE ONLINE
CME/CEU
Prevention,
Diagnosis & Treatment of COPD
-
Supported by Boehringer Ingelheim/Pfizer Inc.
The
Relationship and Impact of Diabetes and
Cardiovascular Disease
- Supported
by Daiichi-Sankyo, Merck and sanofi aventis
Current
Concepts in Managing Dyslipidemia
-
Supported by AstraZeneca
Clinical
and Financial Implications of Wound Care
Management Across the Care
Continuum
- Supported by Kinetic
Concepts, Inc. (KCI)
Schizophrenia:
Improving Outcomes While Managing
Care
- Supported by Bristol-Myers
Squibb and Pfizer, Inc.
The
Physical and Fiscal Impact of Sleep
Disorders
- Supported by Cephalon
and sanofi-aventis
The
Management and Treatment of Parkinson's
Disease
- Supported by Teva
Neuroscience
MS:
The New Treatment Paradigm: A Pathway to Success
for Improved Patient Outcomes
-
Supported by Bayer Healthcare, Inc.
How
to Improve Outcomes in a Patient Population of
Asthmatics
- Supported by
AstraZeneca
Stroke:
Primary and Secondary Prevention
-
Supported by Bristol-Myers Squibb
Economic
Value of the Prevention and Treatment of Diabetic
Ulcers
- Supported by KCI
Management
of the Liver Transplant Patient
-
Supported by Astellas
The
Relationship & Impact of Osteoporosis &
Breast Cancer in Post Menopausal
Women
- Supported by Eli Lilly
Implementation
of Comprehensive RSV Management Plan to Improve
Patient, Provider and Plan
Outcomes
- Supported by MedImmune,
Inc.
Health
Economic Implications of Wound Care and Limb
Preservation
- Supported by KCI,
Inc.
| Journal of Managed Care
Medicine |
|
Journal of Managed Care
Medicine Vol 12, Issue 4 Table of
Contents
 Below
you will find the table of contents for the
current issue of JMCM. You can click
here to visit our main journal page, or
click on each individual article below to visit
their article page and then download the
PDF!
Click
the titles below to visit the indvidual article
download page.
The
Financial Implications of New Episodes of MDD for
Treatment Resistant Versus Stable Depressed
Individuals
C. Daniel
Mullins, PhD, Brian Seal, PhD and Lisa Blatt,
MA
Behavioral
Health Update
Mark
Rosenberg, MD, PHD
Hospital
Contracting Trends
Eric
Faulkner, MPH, Josephine Mauskopf, PhD and Jay
Bae, PhD
The
Management of Metabolic Health in the
Workplace
William Bunn,
III, MD, JD, MPH, Joseph Leutzinger, PhD, Richard
Nevins, MD, John Seibel, MD, FACP, MACE, and Sean
Sullivan, JD
The
Relationship Between Rheumatoid Arthritis and
Heart Failure
Geneva
Briggs, PharmD
Clinical
Utility or Impossibility? Addressing the Molecular
Diagnostics Health Technology Assessment and
Reimbursement
Conundrum
Eric Faulkner,
MPH
Complete
12.4
Issue
| Join NAMCP's LinkedIn
Group! |
|
This is a GREAT way to network with other
members, send them direct messages, post comments
or questions and learn more about your colleagues
working in other areas of managed care! If you are
a member of this professional, social network,
please search groups for NAMCP and request to join
our group for ongoing discussions, networking and
interaction with other
members!
Visit NAMCP's Career
Center!
To find a job or fill a
position, visit http://careers.namcp.org.
You can also click on the links following each
individual job below to be taken to their new page
on our career center.
Job
seekers and employers have discovered the
advantages of searching online for the best jobs
and for qualified candidates to fill them. But,
the mass-market approach of the mega job boards
may not be your best avenue.
NAMCP's Career
Center gives employers and job seeking managed
care professionals a better way to find one
another and make that perfect career
fit.
For Job Seekers: Post your
resume; Search job listings; Set up Search Agents;
and have new postings sent to you via
email.
For Employers: Post your
jobs; Target a focused audience of candidates;
Search resumes; Track applications; Promote your
company online.
If you
would like to post a job on Managed Care eNews,
please contact Sloane Reed at
sreed@namcp.org or 804-527-1905 for
rate information.
In
accordance with our mission, to enhance the
ability of our members to succeed in their
careers, we are pleased to offer comprehensive
career consultation and national executive
placement services. As a benefit of membership for
our client organizations, i.e., anyone seeking to
hire experienced staff, we offer exceptional
executive search services and at a discounted
rate. We have access to the highest caliber of
managed care talent and have a distinguished track
record in placing physician and nurse executives
as well as executive operations personnel (CEO,
COO, CFO, Director of Managed Care, Network
Development, etc.)
If you have an available
position or have an interest in our placement
service, please contact David Mara at
(804)527-1905 or e-mail at dmara@namcp.org.
For a more detailed job description for any of
the jobs listed below, please contact Dave Mara at
804.527.1905 or email him at dmara@namcp.org
You
can also CLICK HERE to visit our Job
Placement and Career Counseling page to view the
full descriptions for all of these jobs and
more!
Medical Director, Clinical Research, North
America
New Jersey
Job
Summary
The Medical Director-Clinical
Research, North America reports to the Executive
Medical Director. The incumbent is responsible for
developing and implementing product development
strategies initially in the Gastroenterology
therapeutic area but later may involve in other
therapeutic areas as derived from the company's
pipeline and/or in licensed development products.
While the individual is expected to manage the
conduct of clinical trials in the US, there is a
strong component involving participation in global
project development teams. The Medical Director
will be expected to undertake all the duties
normally associated with the execution of clinical
trials and to establish clinical advisory boards
in the areas of product development.
For
more information, please call David Mara at
804.527.1905. To review additional positions go to
www.nexushc.com
Medical Director
New
Jersey
Job Summary
The
Medical Director reports to the Vice President of
Infertility and Orthopedics. The incumbent is
responsible for developing and implementing
product development strategies initially in the
OBGYN therapeutic areas but later may involve in
other therapeutic area; as derived from the
company pipeline and/or in licensed development
products. While the individual is expected to
manage the conduct of clinical trials in the US
there is a strong component involving
participation in global project development teams
managed from the company's International Center in
Copenhagen. The Medical Director will be expected
to undertake all the duties normally associated
with the execution of clinical trials and to
establish clinical advisory boards in the areas of
product development.
For more information,
please call David Mara at 804.527.1905. To review
additional positions go to www.nexushc.com
Medical Director, Clinical Research, North
America
New Jersey
Job
Summary
The Medical Director-Clinical
Research, North America reports to the Executive
Medical Director. The incumbent is responsible for
developing and implementing product development
strategies initially in the Urology therapeutic
area but later may involve in other therapeutic
area as derived from the company's pipeline and/or
in licensed development products. While the
individual is expected to manage the conduct of
clinical trials in the US there is a strong
component involving participation in global
project development teams. The Medical Director
will be expected to undertake all the duties
normally associated with the execution of clinical
trials and to establish clinical advisory boards
in the areas of product development.
For
more information, please call David Mara at
804.527.1905. To review additional positions go to
www.nexushc.com
Chief Medical Officer
San Francisco,
CA
Job Summary
The Chief
Medical Officer (CMO) for the Healthcare Services
organization will be integral in the realization
of the health plan's mission, by providing
leadership and direction for health management and
clinical quality improvement strategies, providing
greater value to its members through pharmacy and
medical management, and optimally functioning
management systems.
For more information,
please call David Mara at 804.527.1905. To review
additional positions go to www.nexushc.com
Associate Medical Director
Nashville, TN
Job Summary
Working with the
Chief Medical Director, oversees medical care for
the health plan's products and services and
oversees the health care needs of the membership.
Serves as a medical manager and policy advisor to
the company and health plan Chief Medical
Director. Is accountable for and provides
professional leadership and direction to the
utilization/cost management and clinical quality
management functions. Works collaboratively with
other plan functions that interface with medical
management such as provider relations, member
services, benefits and claims management, etc.
Assists (as determined by the plan Chief Medical
Director) in short and long range program
planning, total quality management (quality
improvement) and external
relationships.
For more information, please
call David Mara at 804.527.1905. To review
additional positions go to www.nexushc.com
Chief Medical Officer
Nashville, TN
Overview
Oversees all
medical care for the health plan's products and
services. Oversees the health care needs of the
membership. Serves as the principal medical
manager and policy advisor to the company and
health plan CEO or COO. Is accountable for and
provides professional leadership and direction to
the utilization/cost management and clinical
quality management functions. Works
collaboratively with other plan functions that
interface with medical management such as provider
relations, member services, benefits and claims
management, etc.
Please
click here to visit the webpage for this
job opportunity, including a detailed job
description!
MEDICARE HMO EXPANDING - NEW MARKET
OPPORTUNITY
Medical Director
Mobile,
AL
Job Summary
This position
is responsible for the administration of all
medical services for the corporation. It is
responsible for the coordination of medical
policy, peer review, quality management,
legal/medical issues, and the effectiveness of the
Medical Management Program.
Please
click here to visit the webpage for this
job opportunity, including a detailed job
description!
Medical Director
Virtual
Job
Summary
A leading healthcare technology and
service company that provides solutions for
healthcare organizations, has a unique experience
base, extensive healthcare information and
advantaged technology applications which create
value through reduced medical costs, reduced
administrative costs and improved care
coordination is seeking a Medical Director to
support a growing client base and maintain their
competitive advantage in the depth of clinical
logic.
The Medical Director is instrumental
within the company in directing the Logic
Committee (Medical Policy Committee) which is
composed of medical directors, coding analysts,
provider relations, contracting people, etc. At
the Logic Committee, the company goes through
their Global Medical Policy document as it relates
to claims coding and then subsequently reviews
individual edits that have potential value for the
client.
Please direct all inquires to Dave
Mara at 804-527-1905.
Manager, Provider Relations and
Contracting
Austin, TX; Ft. Lauderdale; Orlando
and Tampa, FL
Summary
This
behaviorial health company is a multi-line managed
care organization that provides Medicaid-related
programs to organizations and individuals through
government subsidized programs. We have an
excellent opportunity for a Manager of Provider
Relations and Contracting. This position will
implement development activities for the
recruitment, contracting and retention of
providers. Negotiate contracts and develop
strategies and methodologies for specific network
development initiatives.
Please
click here to visit the webpage for this
job opportunity, including a detailed job
description!
| | |
| Managed Care eNews for January 13,
2010 |
Produced by NAMCP, AAMCN, AAIHDS
4435 Waterfront Drive, Suite 101
Glen
Allen, VA 23060
Telephone:
804-527-1905
Fax: 804-747-5316 |
Click "Opt-out of this
newsletter" at the top of the newsletter or
contact Jeremy Williams at jwilliams@namcp.org
or 804-527-1905 to be taken off the
list | | | | |
|
| NAMCP Medical Directors Resource
Centers |
|
The purpose of NAMCP's Medical Directors
Resource Centers is to provide Medical Directors
with access to disease specific information and
resources and to improve patient
outcomes.
Accessing NAMCP's Medical
Directors Resource Centers will allow you
to:
Use screening tools to diagnose
Access treatment and best practice guidelines
Improve patient adherence and compliance
Improve patient outcomes
Better manage patients
Review cost of treatment versus overall
economic burden
Provide resources for your network physicians
Provide resources for patients
CLICK
HERE to access the Obesity Resource
Center
CLICK
HERE to access the Sleep Resource
Center
CLICK
HERE to access the Diabetes Resource
Center
| | |
| NAMCP Behavioral Health Resource
Center |
|
Preventative Behavioral Health Treatment:
Depression
Early treatment and
prevention of Depression can help your heart. Find
out the latest developments on the corollary
relationship between Depression and Heart Disease,
and effective treatment methods for dealing with
these issues. For more info please click
here.
If you are interested in the
NAMCP Behavioral Health Resource Center, please
contact Katie Eads at 804-527-1905 or keads@namcp.org.
| | |
| JOURNAL OF MANAGED CARE MEDICINE
(JMCM) |
|
Vol. 12, No. 4 has been
released! Scroll below to the Journal Section
below for downloadable
articles! | | |
| EMPLOYMENT
OPPORTUNITIES |
|
Call Dave Mara at (804) 527-1905 for
information on any of the following job
openings.
Medical Director, Clinical Research, North
America, New Jersey
Medical Director, New Jersey
Chief Medical Officer, San Francisco, CA
Medical Director, Mobile, AL
Medical Director, Virtual
Chief Medical Officer, Nashville, TN
Manager, Provider Relations and Contracting,
Austin, TX; Ft. Lauderdale, Orlando and Tampa,
FL
VP of Health Services, Birmingham, AL, Miami,
FL and New Orleans, LA
VP, Health Care Management Services, Multiple
Locations
Senior Medical Director, Houston,
TX
For more information or for more
detailed job descriptions, please contact Dave
Mara at 804.527.1905 or email your resume to dmara@namcp.org
| | | |
